2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 728

Correlation Between the Spinal MRI Findings and the Serum Level of DKK-1 in Patients with Spondyloarthritis Treated with TNF Antagonist

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

9:00AM-11:00AM: Abstract Number: 326

Cortical Bone Changes in Pre- and Postmenopausal Healthy Women Measured with HR-pQCT

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

9:00AM-11:00AM: Abstract Number: 253

Corticosteroid-Free Tocilizumab Monotherapy for Adult Onset Still’s Disease: Results in Six Month

Miscellaneous Rheumatic and Inflammatory Diseases - Poster I

9:00AM-11:00AM: Abstract Number: 308

Crepitus As a Risk Factor for Symptomatic Knee Osteoarthritis: Data from the Osteoarthritis Initiative

Osteoarthritis – Clinical Aspects - Poster I

9:00AM-11:00AM: Abstract Number: 448

Cross-Cultural and Construct Validity of the Animated Activity Questionnaire to Assess Activity Limitations in Patients with Hip and Knee Osteoarthritis in Different Languages

Quality Measures and Quality of Care - ARHP Poster

9:00AM-11:00AM: Abstract Number: 451

Cross-Sectional and Longitudinal Construct Validity for the Improved Health Assessment Questionnaire Among Adults with Knee Osteoarthritis

Quality Measures and Quality of Care - ARHP Poster

9:00AM-11:00AM: Abstract Number: 470

Crucial Involvement of Citrullinated Proteins and ACPA in the Development of Peptide-Glucose-6-Phosphate Isomerase Induced Arthritis

Rheumatoid Arthritis – Animal Models - Poster I

9:00AM-11:00AM: Abstract Number: 845

Current Use of Off-Label Therapies in Systemic Sclerosis-Associated Interstitial Lung Disease

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster I

9:00AM-11:00AM: Abstract Number: 667

Cytokine and Chemokine Levels in Serum and Saliva As Disease Activity Biomarkers in Patients with Primary Sjögren’s Syndrome

Sjögren's Syndrome - Poster I: Translational Science

9:00AM-11:00AM: Abstract Number: 663

Cytokine and Chemokine Levels in Serum and Tears As Disease Activity Biomarkers in Patients with Primary Sjögren´s Syndrome

Sjögren's Syndrome - Poster I: Translational Science

9:00AM-11:00AM: Abstract Number: 252

Cytokine Profiles of Korean Patients with Adult Onset Still’s Disease Treated with Biologic Agents

Miscellaneous Rheumatic and Inflammatory Diseases - Poster I

9:00AM-11:00AM: Abstract Number: 98

Daily Symptom Reports in a Smartphone-Based Study ‘Cloudy with a Chance of Pain’: Patterns of Attrition over the First Six Months

Health Services Research - Poster I

9:00AM-11:00AM: Abstract Number: 658

Decreased Expression of Ten Micro-RNAs in Plasmacytoid Dendritic Cells of Patients with Primary SS Indicates Dysregulation on Multiple Levels

Sjögren's Syndrome - Poster I: Translational Science

9:00AM-11:00AM: Abstract Number: 463

Deficiency of Transmembrane Protein VISTA (V-domain Immunoglobulin Suppressor of T-cell Activation) Ameliorates Murine Collagen-II Antibody-Induced Arthritis

Rheumatoid Arthritis – Animal Models - Poster I

9:00AM-11:00AM: Abstract Number: 832

Defining Skin Ulcers in Systemic Sclerosis: A Systematic Literature Review of Skin Ulcer Definitions and a Preliminary Consensus-Based New SSc Skin Ulcer Definition

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].